Navigation Links
Insmed to Present at BioPharm Asia 2008 Conference
Date:9/4/2008

RICHMOND, Va., Sept. 4 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM) a developer of follow-on biologics and biopharmaceuticals, today announced that Geoffrey Allan, Ph.D., CEO of Insmed, will present at the BioPharm Asia 2008 Conference. Dr Allan will be discussing Insmed's experiences to date regarding the regulatory issues surrounding follow-on biologics (FOB) in the U.S. His presentation will take place on Tuesday September 9, 2008 at the Sheraton Towers Hotel in Singapore.

This year's BioPharm Asia conference program will focus on the emerging FOB industry and cover development, manufacturing and marketing of FOB.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, strategic alternatives, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that strategic alternatives may never be consummated, product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow-on biologics market may be unsuccessful, our common stock could be delisted from The NASDAQ Capital Market and other risks and challenges detailed in the Company's filings with the U.S. Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
2. Insmed CEO to Present at Drug Discovery & Development Conference
3. Insmed to Host Second Quarter 2008 Conference Call
4. Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor
5. Insmed Retains RBC Capital Markets as Strategic Financial Advisor
6. Insmed to Present at Collins Stewart Fourth Annual Growth Conference
7. Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination
8. Insmed Announces First Quarter 2008 Financial Results
9. Insmed to Present at CBI Follow-On Biologics Conference
10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
11. Insmed Announces Additional Information in Compliance With NASDAQ Rules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... ... Spyker, PhD, MD former Acting Deputy Director in the FDA CDRH Division of ... Staff has joined the company as an Expert Consultant. , In Dr. Spyker’s ...
(Date:2/21/2017)... , Feb. 21, 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... operational results for the three months ended December 31, 2016. ... -based life sciences and diagnostics company that develops and commercializes ... ... to build on the commercial milestones achieved in fiscal 2016," ...
(Date:2/21/2017)... ... February 21, 2017 , ... The medical potential of stem cells is both ... of medicine, due to their differentiating characteristics. Stem cells are unique as the have ... be induced to become tissue or organic-specific cells with special functions. , Stem ...
(Date:2/21/2017)... 2017  Lexus, a returning partner of the Amgen Tour ... exclusive automobile partner of the men,s and women,s events for the ... 2017 Amgen Tour of California will mark ... the best professional cycling teams in the world racing from Northern ... Amgen Breakaway from Heart Disease TM Women,s Race ...
Breaking Biology Technology:
(Date:2/3/2017)... , Feb. 3, 2017 A new independent ... Strategy Partners, LLP (IdSP) . Designed to fill a ... complex identity market, founding partners Mark Crego ... combined years just in identity expertise that span federal ... non-profit leadership. The Crego-Kephart combined expertise has a common ...
(Date:1/31/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company ... of bacterial infections, today announced it has acquired ... Pro Bono Bio Ltd (PBB) to bolster its ... forms of Gram-negative bacteria.   The assets acquired have ... PBB group company. "The acquisition of ...
(Date:1/24/2017)... Jan. 24, 2017 Biopharm Reports has ... laboratory use of nuclear magnetic resonance spectroscopy (NMR). ... and profiled current practices, developments, trends and end-user ... as growth and opportunities. These areas include growth ... instruments, needs and innovation requirements, hyphenated NMR techniques, ...
Breaking Biology News(10 mins):